Martin Bonde leaves consultancy firm for CEO position in Swiss company
Experienced biotech leader Martin Bonde leaves Danish Novo Seeds' consultancy firm Biorigin to become CEO of a Swiss cancer company, where Novo Seeds is also a major investor. "I just had to accept," he says.
BY ALBERT RØNNING-ANDERSSON, TRANSLATED BY IDA LØJMAND
Almost ten months after Martin Bonde stepped down after four years as CEO of Norwegian Vaccibody, the experienced biotech leader has found a new top position, this time in Switzerland.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Martin Bonde silent about reason for Vaccibody exit
For abonnenter
